早期氟脱氧葡萄糖-正电子发射断层扫描缓解成像与外周免疫生物标志物的预后价值:不可切除非小细胞肺癌风险适应性放化疗II期试验的子研究
该II期试验子研究纳入45例不可切除IIB-IIIB期非小细胞肺癌患者,同步放化疗期间(24 Gy后)行氟脱氧葡萄糖-正电子发射断层扫描评估缓解,并同步分析外周血T细胞受体测序与细胞因子。中位随访18.8个月,1年总生存率82%、无进展生存率53%、局部区域控制率88%。中期PET总病灶糖酵解较高与总生存、无进展生存及局部区域控制较差相关;PET缓解可能与肿瘤及外周T细胞生物标志物相关。
要点
- 中期PET总病灶糖酵解较高与1年总生存87% vs 63%、无进展生存60% vs 26%、局部区域控制94% vs 65%较差相关。
- 45例中29例(64%)按预设定义归类为PET缓解者。
- 肿瘤程序性死亡配体1表达较高与PET缓解相关(P = .017)。
核心结论
- 放化疗中期PET成像对生存具有预后价值。
- PET缓解可能与肿瘤及外周T细胞生物标志物相关。
研究设计与样本
- II期试验子研究,纳入45例美国癌症联合委员会第7版IIB-IIIB期不可切除非小细胞肺癌患者(NCT02773238)。
- 患者接受铂类双药化疗联合同步6周放疗;治疗前及放疗24 Gy后(第3周)行氟脱氧葡萄糖-正电子发射断层扫描。
- PET缓解状态由多因素放射学判读前瞻性定义;PET缓解者接受60 Gy/30次,非缓解者接受同步加量至74 Gy/30次。
- 外周血与PET成像同步采集,进行胚系DNA测序、T细胞受体测序及血浆细胞因子分析。
主要发现
- 中位随访18.8个月,1年总生存率82%,1年无进展生存率53%,1年局部区域控制率88%。
- 中期PET总病灶糖酵解较高与总生存较差相关(1年87% vs 63%,P < .001),与无进展生存较差相关(1年60% vs 26%,P = .044),与局部区域控制较差相关(1年94% vs 65%,P = .012),调整临床/治疗因素后仍显著。
- 45例中29例(64%)按预设定义归类为PET缓解者。
- 肿瘤程序性死亡配体1表达较高与PET缓解相关(P = .017)。
- T细胞受体丰富度及克隆分布斜率较高与总生存改善相关(P = .018-0.035);克隆分布斜率与PET缓解相关(P = .031)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to examine the prognostic value of fluorodeoxyglucose-positron emission tomography (PET) imaging during chemoradiation for unresectable non-small cell lung cancer for survival and hypothesized that tumor PET response is correlated with peripheral T-cell function. METHODS AND MATERIALS: Forty-five patients with American Joint Committee on Cancer version 7 stage IIB-IIIB non-small cell lung cancer enrolled in a phase II trial and received platinum-doublet chemotherapy concurrent with 6 weeks of radiation (NCT02773238). Fluorodeoxyglucose-PET was performed before treatment start and after 24 Gy of radiation (week 3). PET response status was prospectively defined by multifactorial radiologic interpretation. PET responders received 60 Gy in 30 fractions, while nonresponders received concomitant boosts to 74 Gy in 30 fractions. Peripheral blood was drawn synchronously with PET imaging, from which germline DNA sequencing, T-cell receptor sequencing, and plasma cytokine analysis were performed. RESULTS: Median follow-up was 18.8 months, 1-year overall survival (OS) 82%, 1-year progression-free survival 53%, and 1-year locoregional control 88%. Higher midtreatment PET total lesion glycolysis was detrimental to OS (1 year 87% vs 63%, P < .001), progression-free survival (1 year 60% vs 26%, P = .044), and locoregional control (1 year 94% vs 65%, P = .012), even after adjustment for clinical/treatment factors. Twenty-nine of 45 patients (64%) were classified as PET responders based on a priori definition. Higher tumor programmed death-ligand 1 expression was correlated with response on PET (P = .017). Higher T-cell receptor richness and clone distribution slope were associated with improved OS (P = .018-0.035); clone distribution slope was correlated with PET response (P = .031). CONCLUSIONS: Midchemoradiation PET imaging is prognostic for survival; PET response may be linked to tumor and peripheral T-cell biomarkers.
引用
- Bowen SR, Hippe DS, Thomas HM, et al. Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer. Adv Radiat Oncol. 2021. PMID: 35387421. doi:10.1016/j.adro.2021.100857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。